by David Cassak
Having spent much of the 1980s acquiring a wide array of product lines, mostly in the US—every thing from orthopedic...
In the late 1980s, medical supply companies sought to leverage their relationships with new customers by creating a broad portfolio of diverse products. Smith & Nephew is pursuing a different tack--having spent a decade making one acquisition after another, it spent the last several years selling off most of those businesses. What remains is a company focused on products that repair tissue, in areas such as orthopedics, wound care, and endoscopy.
by David Cassak
Having spent much of the 1980s acquiring a wide array of product lines, mostly in the US—every thing from orthopedic...
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.